Unlike the 2021 peak where M&A and equity issuance were balanced, the recent biotech surge sees M&A at over double the rate of new equity. This indicates that big pharma's need for growth due to patent cliffs is the primary driver, not speculative new investments.
The resurgence in biotech IPOs is marked by a significant shift towards selectivity. There have been zero preclinical IPOs this cycle, a stark contrast to the 19 that went public before the last peak, indicating investors now demand more mature assets with clinical data.
Moderna's positive trial results drove a stock surge fueled by generalist investors. This frustrated many specialist biotech funds who were short the stock or didn't hold it, causing them to underperform their benchmark and complain about "unsophisticated" capital.
Moderna's cancer vaccine's long-term value may lie in its proprietary neoantigen selection algorithm. As a trade secret, it can't be easily replicated, effectively preventing generic competition indefinitely and creating a highly durable franchise as long as the treatment remains effective.
RASONQ's label allows its use as a first-line treatment for pancreatic cancer patients ineligible for chemotherapy. This will likely drive its use earlier in treatment, complicating the design and enrollment of future clinical trials for competing drugs in both first- and second-line settings.
A proposal to require recent FDA audits for clinical trial data from China is gaining traction. The involvement of Rep. Ben Klein, a member of the typically industry-friendly Biotech Caucus, indicates that this concern is expanding beyond its usual critics and becoming a more mainstream political issue.
The CardioTransform study showed that adding a gene silencer to a stabilizer for ATTR cardiomyopathy provided no cardiovascular benefit and suggested potential harm. This undermines the rationale for combination therapy and questions the incremental value of the entire silencer class over existing stabilizers.
After their ALS drug failed a confirmatory study, Amalix's management team took the rare step of pulling it from the market. This ethical decision earned them immense credibility with investors, likely paving the way for a highly successful $500M financing for their next drug.
The extreme pricing of some new drugs leads analysts to question the valuation logic. One theory is that companies determine a revenue goal, then simply divide it by the eligible patient population to arrive at a price, rather than basing it on R&D costs or clinical value.